US Food and Drug Administration Approval Overview in Metastatic Breast Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2012 Mar 21

PMID 22430273

Citations 29

Authors

Patricia Cortazar

Robert Justice

John Johnson

Rajeshwari Sridhara

Patricia Keegan

Richard Pazdur

Affiliations

Soon will be listed here.

Citing Articles

Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches.

da Cunha Lyrio R, Rocha B, Correa A, Mascarenhas M, Santos F, Maia R Front Nephrol. 2024; 4:1436896.

PMID: 39185276 PMC: 11341478. DOI: 10.3389/fneph.2024.1436896.

Using Pointwise Mutual Information for Breast Cancer Health Disparities Research With SEER-Medicare Claims.

Egleston B, Chanda A, Bai T, Fang C, Bleicher R, Vucetic S Methodology (Gott). 2023; 19(1):43-59.

PMID: 37090814 PMC: 10121207. DOI: 10.5964/meth.8535.

Paclitaxel induces pyroptosis by inhibiting the volume‑sensitive chloride channel leucine‑rich repeat‑containing 8a in ovarian cancer cells.

Yang X, Li C, Liao X, Liu S, Li X, Hou X Oncol Rep. 2023; 49(6).

PMID: 37083067 PMC: 10170489. DOI: 10.3892/or.2023.8552.

Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy.

Hawash M Biomolecules. 2022; 12(12).

PMID: 36551271 PMC: 9776383. DOI: 10.3390/biom12121843.

Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials.

Huang Q, Mei Z, Han X Front Oncol. 2022; 12:972767.

PMID: 36119468 PMC: 9471016. DOI: 10.3389/fonc.2022.972767.

References

Blum J, Jones S, Buzdar A, LoRusso P, Kuter I, Vogel C . Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17(2):485-93. DOI: 10.1200/JCO.1999.17.2.485. View

Broglio K, Berry D . Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009; 101(23):1642-9. PMC: 4137232. DOI: 10.1093/jnci/djp369. View

Gradishar W, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7794-803. DOI: 10.1200/JCO.2005.04.937. View

Van Oosterom A . Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol. 1995; 22(6 Suppl 13):22-8. View

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-76. DOI: 10.1056/NEJMoa072113. View

Nabholtz J, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P . Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996; 14(6):1858-67. DOI: 10.1200/JCO.1996.14.6.1858. View

AHern R, Smith I, Ebbs S . Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer. 1993; 67(4):801-5. PMC: 1968345. DOI: 10.1038/bjc.1993.146. View

Korn E, Freidlin B, Abrams J . Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011; 29(17):2439-42. PMC: 3107757. DOI: 10.1200/JCO.2011.34.6056. View

Albain K, Nag S, Calderillo-Ruiz G, Jordaan J, Llombart A, Pluzanska A . Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008; 26(24):3950-7. DOI: 10.1200/JCO.2007.11.9362. View

10.

OShaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J, Cervantes G . Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20(12):2812-23. DOI: 10.1200/JCO.2002.09.002. View

11.

Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L . Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17(9):2639-48. DOI: 10.1200/JCO.1999.17.9.2639. View

12.

Nabholtz J, Senn H, Bezwoda W, Melnychuk D, Deschenes L, Douma J . Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999; 17(5):1413-24. DOI: 10.1200/JCO.1999.17.5.1413. View

13.

Gray R, Bhattacharya S, Bowden C, Miller K, Comis R . Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009; 27(30):4966-72. PMC: 2799052. DOI: 10.1200/JCO.2008.21.6630. View

14.

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu C . A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008; 112(3):533-43. DOI: 10.1007/s10549-007-9885-0. View

15.

Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733-43. DOI: 10.1056/NEJMoa064320. View

16.

Fossati R, CONFALONIERI C, Torri V, GHISLANDI E, Penna A, Pistotti V . Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998; 16(10):3439-60. DOI: 10.1200/JCO.1998.16.10.3439. View

17.

Saad E, Katz A, Buyse M . Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010; 28(11):1958-62. DOI: 10.1200/JCO.2009.25.5414. View

18.

Paridaens R, Biganzoli L, Bruning P, Klijn J, Gamucci T, Houston S . Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000; 18(4):724-33. DOI: 10.1200/JCO.2000.18.4.724. View

19.

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

20.

. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79. PMC: 1629006. DOI: 10.1186/1477-7525-4-79. View